Kyntra Bio Inc (KYNB)

Jan 7, 2026, 7:30 AM EST - 3 days ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Nov 10, 2025, 10:01 PM EST - 2 months ago

FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:02 PM EST - 2 months ago

FibroGen to Report Third Quarter 2025 Financial Results

Sep 24, 2025, 7:00 AM EDT - 3 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Aug 27, 2025, 4:02 PM EDT - 4 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 5 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 11:55 PM EDT - 5 months ago

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:02 PM EDT - 5 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 5 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 13, 2025, 8:22 AM EDT - 7 months ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

Jun 12, 2025, 4:02 PM EDT - 7 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 7 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 10:31 PM EDT - 8 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:02 PM EDT - 8 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 8 months ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 8 months ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 2, 2025, 4:05 PM EDT - 10 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 8:18 PM EDT - 10 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:05 PM EDT - 10 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 11 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 1:08 PM EST - 11 months ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

Feb 20, 2025, 6:40 AM EST - 11 months ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 11 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 8:38 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 6, 2024, 12:38 PM EDT - 1 year ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 3, 2024, 4:05 PM EDT - 1 year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 1 year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 2, 2024, 5:46 PM EDT - 1 year ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 11:44 PM EST - 2 years ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer